Ohio is currently home to 3203 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 with Low Dose Targeted Busulfan Conditioning
NCT03311503
Recruiting
This is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years and be followed for 2 years post-infusion on this protocol, then followed long-term on a separate long-term follow-up protocol. Enrollment of subjects will be agreed upon by representatives of both sites. Data will be... Read More
Gender:
MALE
Ages:
Between 0 years and 5 years
Trial Updated:
01/03/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Severe Combined Immunodeficiency, X Linked, Gene Therapy
Register for Updates
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
NCT06616623
Recruiting
This phase Ib trial tests the safety, side effects, and best dose of the combination of vismodegib and atezolizumab in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or has spread from where it first started (primary site) to other places in the body (metastatic). Vismodegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizuma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC V8
Register for Updates
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients with Advanced Cancer, CIRES Trial
NCT06470971
Recruiting
This phase II trial studies how well giving siltuximab during the reintroduction (rechallenge) of immune checkpoint inhibitor (ICI) therapy works in preventing severe immune-related adverse events (irAEs) in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immune checkpoint inhibitors, such as anti-PD1 and anti-PD-L1 monoclonal antibodies, may help the body's immune system attack the cancer, and may inte... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063
Recruiting
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.
Gender:
FEMALE
Ages:
Between 15 years and 55 years
Trial Updated:
01/02/2025
Locations: University o Cincinnati, Cincinnati, Ohio
Conditions: Cesarean Delivery, General Anesthesia
Register for Updates
Mind Body Balance for Pediatric Migraine
NCT04715685
Recruiting
This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
01/02/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Register for Updates
LUng voluMe reductIoN by DuAl ENergy CT Evaluation (LUMINANCE) Study
NCT05816239
Recruiting
The purpose of this research study is to see if a special CT scan (dual-energy CT) provides useful information in patients undergoing bronchsoscopic lung volume reduction (valve placement for emphysema). The investigators will enroll up to 30 participants in this study from University Hospitals Cleveland Medical Center. All of the participants from this study will undergo their valve procedure at University Hospitals Cleveland Medical Center.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/31/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Lung Perfusion
Register for Updates
Osimertinib and Tegavivint As First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
NCT04780568
Recruiting
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/31/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma
NCT06344143
Recruiting
The aim of the proposed study is to estimate the incidence of Mild Autonomous Cortisol Secretion (MACS) in patients with Adrenal Incidentaloma (AI) and evaluate the available diagnostic tests to determine the most sensitive and specific combination of tests for assessing MACS from adrenal adenoma for prediction of the phenotype associated with cortisol excess. As well as following the patients for 4 years and see if anything changes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: The Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Mild Autonomous Cortisol Secretion (MACS)
Register for Updates
Investigating NMJ Defects in SMA Following Central and Peripheral SMN Restoration
NCT05219487
Recruiting
This is an observational study to investigate the improvement of NMJ defects in adult patients with SMA following treatment with Risdiplam. Eligible patients will have received treatment with daily oral Risdiplam after receiving approval through their commercial insurance or drug assistance program. All subjects will be evaluated at one visit. Eligible subjects must have been receiving risdiplam for at least 12 months.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/30/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Spinal Muscular Atrophy
Register for Updates
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
NCT01954992
Recruiting
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: Gabrail Cancer Center Research, Canton, Ohio
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
NCT05814666
Recruiting
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: The Christ Hospital Cancer Center, Cincinnati, Ohio
Conditions: HNSCC
Register for Updates
Anti-pneumococcal Vaccine Strategy in Patients with Chronic Lymphocytic Leukemia
NCT05417165
Recruiting
This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vaccination. Current vaccination schedule for chronic lymphocytic leukemia patients is based on general recommendations in immunocompromised patients (initial vaccination with PCV13 followed by one dose o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates